SPY434.04-7.36 -1.67%
DIA339.40-6.24 -1.81%
IXIC14,713.90-330.07 -2.19%

US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med

Benzinga · 09/01/2021 09:03
  • The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) Rapivab (peramivir injection)
  • The govt will pay approximately $7 million for the Antiviral influenza therapy. The Rapivab purchase will supply the Strategic National Stockpile.
  • The order is part of a $34.7 million contract the Centers for Disease Control and Prevention awarded in 2018 to procure up to 50,000 doses of Rapivab over five years for the SNS. 
  • With the fulfillment of this new order, BioCryst will have delivered 40,000 doses under the contract.
  • Rapivab is approved in the U.S. for acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days. 
  • Price Action: BCRX shares are up 1.57% at $16.17 during the premarket session on the last check Wednesday.